The pharmaceutical company Darnitsa invested EUR10 million in technological projects in 2019, Dmytro Shymkiv, the chairman of the board of directors of Darnitsa Group, has said.
“In 2019, we invested EUR10 million in technology projects, research, development and production of new drugs. This is 24% more than in 2018,” he said in an interview with Interfax-Ukraine.
Shymkiv said that the structure of Darnitsa’s investments includes three areas: about 48% is investment in new products, 34% in technological development and 16% in digitalization.
Darnitsa invested EUR 2.33 million in digitalization, and more than EUR 30 million in new products in 2015-2019.
He noted that in 2020, Darnitsa launched nine new products in therapeutic areas such as cardiology, neurology, mental health, and completed eight bioequivalence studies of its drugs in the EU, six more studies are ongoing.
